Insights
white paper
FDA's Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER's Rating System?
Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...
white paper
Bispecific antibodies unleashed
Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising ther...
article
CMC Best Practices: Expediting Orphan Drug Development to Combat Rare Disease
February 28 marks the global observance of Rare Disease Day, a day when we participate in raising awareness and generating change for the global population and their families living with rare diseases.
fact sheet
Comprehensive mRNA Solutions
Partner with Curia for combined expertise, speed and reliability to support the research, development and manufacturing of your mRNA product.
article
The M.O. Behind Choosing a CDMO: Three Considerations for New Drug Developers
For many who are new to drug development, the greatest challenge is not necessarily discovering a blockbuster molecule—it’s finding a team capable of carrying that molecule through the complexities that lie between the research lab and the patien...
article
Rapid Drug Manufacturing Scale-Up: Best Practices
As pandemic conditions persist, the pharma industry continues to respond as rapidly as possible to bring more vaccine options to the global population. But developing one or more effective vaccines was just the first hurdle to clear. The drug industr...
webinar
Casual Nexus – Episode Two: T3P - A Versatile Peptide Coupling and Water Removal Reagent
Presenters: Peter Talbiersky, Ph.D., Manager of Fine Chemicals Sales, Curia Listen in as our experts discuss: The importance of a green and versatile condensation reagent Safe alternative for commonly used condensation reagents like dicyclohe...
article
From Niche to Transformational: Using Biology for Chemistry in Pharmaceutical Development
Though synthetic biology may be regarded as a new or emerging field of science, the concept of applying biological systems to improve chemical synthesis goes back hundreds — arguably, thousands — of years. From the earliest fermentation processes...
webinar
Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production
In this free webinar, the featured speaker will explore the key advances and critical hurdles for translating these emerging molecular biology technologies into real-world applications and commercial processes. Topics for discussion will include: a b...
webinar
Key Considerations for End-to-End Primary Packaging Solutions for Pharmaceuticals & Devices
The objective of this webinar is to address United States Pharmacopeia (USP) and FDA regulatory trends to demonstrate how to integrate various analytical tests into a robust program that addresses product integrity/compatibility throughout the produc...
webinar
Solid Form Selection in Drug Development
Drug formulators should consider the physical properties of their products during pharmaceutical drug development. The physical properties of a solid drug substance are highly dependent on the solid form. It is critical to understand the solid form l...
article
Creating Compound Screening Libraries that Address the Challenges of Drug Discovery
From target discovery through launching a finished product to market, developing a new drug is a complex process which takes on average 10-15 years and costs around 2.6 billion dollars. Early on, this process often involves a high-throughput screenin...
